UnitedHealthcare's Stock Decline and Regulatory Scrutiny

This chapter examines the significant drop in UnitedHealthcare's stock price due to allegations of upcoding practices linked to a Department of Justice investigation. It explores the implications of these accusations for the healthcare industry, especially regarding government payments, and discusses the broader impact of regulatory scrutiny on the company's operations and reputation. Additionally, the chapter reflects on the challenges facing the managed care business amid rising medical costs and the potential for stabilization in care demand post-pandemic.